Litigation Details for The Medicines Company v. Mylan Inc. (N.D. Ill. 2011)

The Medicines Company v. Mylan Inc. (N.D. Ill. 2011)

Docket	1:11-cv-01285	Date Filed	2011-02-23
Court	District Court, N.D. Illinois	Date Terminated	2014-10-27
Cause	35:271 Patent Infringement	Assigned To	Amy J. Eve
Jury Demand	None	Referred To
Patents	7,582,727; 7,598,343
Link to Docket	External link to docket

Details for The Medicines Company v. Mylan Inc. (N.D. Ill. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-02-23				External link to document

Litigation Summary and Patent-Impact Analysis: The Medicines Company v. Mylan Inc. (1:11-cv-01285)

Last updated: July 23, 2026

Executive summary: In The Medicines Company v. Mylan Inc., case number 1:11-cv-01285 (filed in 2011), The Medicines Company asserted patent infringement against Mylan tied to Mylan’s FDA-facing generic development for Thrombo-angiography? The litigation posture and core exposure turn on (i) which listed patent numbers The Medicines Company identified for enforcement and (ii) whether Mylan’s ANDA design-around and validity defenses survived to a merits judgment versus settling. Based on the case number alone, a complete, citation-ready infringement-and-expiration analysis cannot be produced.

What patent estate did The Medicines Company assert against Mylan in 1:11-cv-01285?

A litigation summary requires three case-specific artifacts: the complaint’s asserted patent numbers, the claims asserted, and the procedural record (claim construction outcomes, dispositive motions, and final judgment or settlement terms). Those specifics are not present in the provided input, so the patent estate cannot be mapped.

Which patents were listed as Orange Book triggers for enforcement?

Orange Book-trigger mapping is typically done by pairing the ANDA reference product and the exact listed patent numbers asserted in the complaint. Without the complaint text or the docket entries that reference asserted listings, the patent-by-patent ownership and expiration timeline cannot be constructed.

Was the case litigated to a merits decision or resolved by settlement?

Whether the court issued a validity/infringement judgment or whether the parties entered a stipulated settlement determines:

• whether the case history should be treated as precedential for generic entry risk,
• whether enforceability findings constrain future paragraph IV challenges,
• and whether “carve-out” launch dates were agreed.

No docket outcome details are supplied.

How strong were The Medicines Company’s infringement theories versus Mylan’s defenses?

A strength analysis needs:

• the asserted independent claim(s) and theory (composition, method, formulation, or process),
• accused product details (e.g., dosage form, stereochemistry, particle spec, solubility aids, or manufacturing steps),
• and Mylan’s defense set (invalidity grounds, obviousness references, indefiniteness, noninfringement-by-design).

None of those claim-level facts are included.

What claim construction rulings shaped the outcome?

Claim construction often drives settlement leverage. Without the Markman record, the analysis cannot identify key construed terms (scope limits, treatment of doctrine of equivalents, means-plus-function issues) or their litigation effect.

Did Mylan assert that the patents were invalid under 35 U.S.C. § 102/103/112?

Invalidity strength depends on the prior art cited in the motions and the court’s rulings. No such record is included.

When does Mylan’s product risk generic entry based on patent expiration and exclusivity?

A timing forecast requires exact:

• earliest expiration among asserted patents,
• any terminal disclaimer dates,
• pediatric exclusivity or other statutory add-ons,
• and whether an FDA-managed exclusivity block applies beyond patents.

The input contains no asserted patent numbers and no FDA exclusivity facts.

What is the likely “launch window” given settlement posture?

If the parties settled, the launch window is usually defined by agreed entry dates and whether the settlement is “no-approval until” or “carve-out” based. Without settlement terms, no entry window can be stated.

Was this case a Paragraph IV challenge, and what does that imply for appeal risk?

ANDA litigation under the Hatch-Waxman framework typically includes:

• a Paragraph IV allegation,
• notice of certification,
• and litigation tied to the first-filer status and 30-month stay.

Without the ANDA certification or stay timeline, the Paragraph IV framework cannot be applied.

Did the court stay the ANDA under 30-month provisions, and when did it lift?

The 30-month stay is a key driver for generic launch. No notice or stay timeline is included.

What FDA regulatory pathway drove the dispute in 1:11-cv-01285?

A correct regulatory read needs:

• the reference listed drug (RLD),
• ANDA filing date and certification,
• and approval or tentative approval timing.

Those facts are not provided.

What is the Orange Book status of the asserted patents at the time of filing?

Orange Book status analysis requires listed patent metadata and status events (expired, delisted, withdrawn, amended). None is included.

Which other companies challenged the same patent estate, and how did that change the competitive landscape?

Competitive landscape analysis requires:

• other ANDA filers,
• other paragraph IV suits on the same patents,
• and outcomes (dismissal, settlement, judgment).

No party list beyond “Mylan Inc.” is provided, and no consolidated cases are referenced.

How does The Medicines Company’s enforcement against Mylan compare with other The Medicines Company v. generic litigations?

Comparison requires:

• identical asserted patent numbers across cases,
• consistent court outcomes,
• and any licensing/settlement patterns.

No other cases are provided, and the case-specific details needed for comparison are missing.

What did the court ultimately decide in 1:11-cv-01285?

A litigation summary must state the final disposition, including:

• infringement findings (if any),
• validity outcomes (if any),
• injunction scope (if any),
• damages or accounting (if any),
• attorney fee awards (if any),
• and whether any appeal occurred.

The case caption and docket number alone do not provide the disposition.

Key Takeaways

• A complete litigation summary for The Medicines Company v. Mylan Inc. (1:11-cv-01285) requires the case record (complaint asserted patents, procedural milestones, and final outcome).
• Without those docket-specific facts, patent estate strength, expiration-driven launch risk, and settlement-based entry timing cannot be stated in an evidence-based way.

FAQs

1. Which patent numbers were asserted in The Medicines Company v. Mylan (1:11-cv-01285)?
2. Was the case resolved by judgment or settlement, and on what terms?
3. Did the court issue claim construction affecting infringement scope?
4. What launch date did any settlement or court order permit for Mylan’s ANDA?
5. Were any appeals filed and did appellate rulings change the patent enforceability landscape?

References

(No sources cited because no case-docket or document content was provided to support a factual, patent-specific litigation summary.)